Carl H. June
Developed the CD19 CAR-T therapy that became the first approved gene-modified cell therapy for cancer.
Led the CTL019 programme, including Emily Whitehead's treatment in 2012, culminating in the approval of tisagenlecleucel in 2017; his centre developed the 4-1BB CAR design used widely today.
| Title | Journal | Year |
|---|---|---|
| Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | New England Journal of Medicine | 2011 |
| Chimeric antigen receptor T cells for sustained remissions in leukemia | New England Journal of Medicine | 2014 |
ELIANA turned CAR-T from a single-centre experiment into a licensed product and created the regulatory and logistical template every later cell therapy has followed. For children with refractory leukaemia it offers a chance of durable remission without transplant. The trial also exposed the gaps: manufacturing failures, patients dying while waiting, and roughly half relapsing within a few years.
This paper is the proof-of-concept for a living drug: a single infusion of a patient's own engineered T cells could eradicate leukaemia that had survived chemotherapy, transplant and antibody therapy. It defined cytokine release syndrome and its antidote, tocilizumab, and revealed antigen-loss relapse. It led directly to the first approved gene-modified cell therapy three years later.
Pages like this
not linked directly; found by shared links- PersonDavid L. Porter
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania.
- TrialELIANA
Shares Emily Whitehead, Tisagenlecleucel, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, CD19.
- PersonBruce L. Levine
Shares Emily Whitehead, Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL, ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, Abramson Cancer Center, University of Pennsylvania.
- PersonStanley R. Riddell
Shares CD19, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Diffuse large B-cell lymphoma.
- Key paperJULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma
Shares Tisagenlecleucel, Abramson Cancer Center, University of Pennsylvania, CD19, Diffuse large B-cell lymphoma.
- ProductObecabtagene autoleucel
Shares ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL, CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- PersonJae H. Park
Shares CD19, Acute lymphoblastic leukaemia, CAR-T cell therapy.
- TrialTRANSCEND CLL 004
Shares CD19, Chronic lymphocytic leukaemia, CAR-T cell therapy.